InvestorsObserver
×
News Home

Will Vertex Pharmaceuticals Incorporated (VRTX) Beat the Rest of the Stocks in the Healthcare Sector?

Friday, December 08, 2023 03:27 PM | InvestorsObserver Analysts

Mentioned in this article

Will Vertex Pharmaceuticals Incorporated (VRTX) Beat the Rest of the Stocks in the Healthcare Sector?

Vertex Pharmaceuticals Incorporated (VRTX) is around the top of the Healthcare sector according to InvestorsObserver. VRTX received an overall rating of 74, which means that it scores higher than 74% of stocks. Additionally, Vertex Pharmaceuticals Incorporated scored a 89 in the Healthcare sector, ranking it higher than 89% of stocks in that sector.

Overall Score - 74
VRTX has an Overall Score of 74. Find out what this means to you and get the rest of the rankings on VRTX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Vertex Pharmaceuticals Incorporated Stock Today?

Vertex Pharmaceuticals Incorporated (VRTX) stock has fallen -0.83% while the S&P 500 is higher by 0.39% as of 3:21 PM on Friday, Dec 8. VRTX has fallen -$2.96 from the previous closing price of $353.95 on volume of 787,984 shares. Over the past year the S&P 500 has risen 16.15% while VRTX is higher by 9.24%. VRTX earned $13.32 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 26.33. Click Here to get the full Stock Report for Vertex Pharmaceuticals Incorporated stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App